These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453 [TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358 [TBL] [Abstract][Full Text] [Related]
4. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344 [TBL] [Abstract][Full Text] [Related]
5. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation. Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of LRRK2: from kinase to substrate. Lobbestael E; Baekelandt V; Taymans JM Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873 [TBL] [Abstract][Full Text] [Related]
7. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946 [TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021 [TBL] [Abstract][Full Text] [Related]
11. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Lobbestael E; Zhao J; Rudenko IN; Beylina A; Gao F; Wetter J; Beullens M; Bollen M; Cookson MR; Baekelandt V; Nichols RJ; Taymans JM Biochem J; 2013 Nov; 456(1):119-28. PubMed ID: 23937259 [TBL] [Abstract][Full Text] [Related]
12. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745 [TBL] [Abstract][Full Text] [Related]
13. Triazolopyridazine LRRK2 kinase inhibitors. Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015 [TBL] [Abstract][Full Text] [Related]